Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "T-Cell Immunotherapy Landscape" report has been added to ResearchAndMarkets.com's offering.
This report investigates the impacts and development of T-Cell Immunotherapies within the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes within the market and how best to pivot to prioritize future changes in the market.
Scope
This report gives important, expert insight you won't find in any other source. Figures throughout the report illustrate major points and trends within the T-Cell Immunotherapy market delving deep into forecasted sales and company pipelines.
This report is required reading for:
- Investors that want to understand past trends impacting the T-Cell Immunotherapy landscape as well as identifying companies to invest in
- Companies that are interested in entering the T-Cell Immunotherapy landscape and where best to focus on
- Large pharma companies with investment groups or BD teams looking to see which companies lead the T-Cell Immunotherapy landscape in the past and how they led
- Small and medium pharma who want to focus their T-Cell Immunotherapy drug portfolio on future trends and are looking for partnership opportunities
Reasons to Buy
- Insights on the different types of T-Cell Immunotherapies with current and novel forms
- Insights on past trends and changes that have informed the T-Cell Immunotherapy market
- Insights on the current leading T-Cell Immunotherapy drugs based on their Sales and Forecasts and other parameters
- Therapeutic and Indication insights into the T-Cell Immunotherapy market
- Insights into the future opportunities for T-Cell Immunotherapies and the companies leading in the market.
Key Topics Covered:
Introduction to T-Cell Immunotherapy
T-Cell Immunotherapies: Previous Years in Review
- T-Cell Immunotherapies: split by subtype
- Top indications
- Most popular T-cell immunotherapy targets
- T-cell immunotherapies split by development stage
- Most active companies in T-cell immunotherapy development
T-Cell Immunotherapies: Future Outlook
- Top companies by T-cell immunotherapy forecast sales
- Total T-cell immunotherapy market forecast sales
- Top T-cell immunotherapies by forecast sales
- Upcoming T-cell Immunotherapy launches
Key Findings
List of Figures
- Timeline of T-cell immunotherapy approvals, split out by subtype
- Patent applications and grants for T-cell immunotherapies (2009-24)
- Review designations awarded, 2012-24
- Types of review designations awarded to TCIs (2004-24)
- Deals by Volume and Value, 2010-24
- Active T-cell immunotherapies split out by their subtype
- Active T-cell immunotherapies split out by indication
- Top targets by drug count: active T-cell immunotherapies
- Active T-cell immunotherapies split out by their highest development stage
- Top companies by number of active T-cell immunotherapies in their portfolio
- Deals by Type in 2024
- Top 5 companies by total TCI sales, 2024-30
- Top Drugs by Sales, 2025
- Total Market Sales, 2017-30
- T-cell immunotherapy expected launches
Company Coverage:
- Novartis
- Bristol-Myers Squibb Co
- Shenzhen Geno-Immune Medical Institute
- Angeles Therapeutics Inc
- Anocca AB
- Shanghai Yake Biotechnology Co Ltd
- Wellington Zhaotai Therapies Ltd
- Bristar Immunotech Biotechnology Co Ltd
- PersonGen BioTherapeutics (Suzhou) Co Ltd
- Adaptimmune Therapeutics Plc
- TScan Therapeutics Inc
- Johnson & Johnson
- Gilead Sciences Inc
- Legend Biotech Corp
- Atara Biotherapeutics Inc
For more information about this report visit https://www.researchandmarkets.com/r/446a7x
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
